Overview
Nosis Bio develops cell-targeted RNA medicines using its Connexa platform, which combines physics-informed deep learning, generative AI, and high-throughput biochemistry to design Targeted Delivery Vehicles for RNA therapies. Connexa builds a receptome atlas mapping human receptors, identifying over 2,900 cell-specific targets to allow gene silencing in precise cell types, including difficult tissues like the CNS. The company pursues a wholly owned pipeline while partnering with big pharma to apply its platform to high-value indications. Its goal is to enable safer, re-dosable RNA medicines that reach previously hard-to-target tissues, expanding treatment options for fibrosis, immune and cardiovascular diseases.
Work here?Claim your company
Simplify's take
What believers are saying
- Johnson & Johnson expanded collaboration on March 24, 2026, adding neurology.
- Nosis nominated a lead fibrosis development candidate on July 31, 2025.
- Bakar Labs spotlighted Nosis on November 2, 2026, signaling durable external validation.
What critics are saying
- Indexed.vc shows only $8.5 million seed funding in September 2024; runway looks tight.
- Public funding disclosures stop after 2024, limiting clinic-scale execution and aggressive hiring.
- If CNS delivery fails, Connexa's platform thesis collapses by 2027.
What makes Nosis Bio unique
- Connexa pairs physics-aware generative AI with a receptor atlas for cell-targeted RNA delivery.
- Nosis mapped 2,900 receptors across 532 cell types, reaching extrahepatic organs.
- Johnson & Johnson and Daiichi Sankyo validate Connexa across neurology and chronic disease.
Help us improve and share your feedback! Did you find this helpful?